Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H14O3.H3N |
| Molecular Weight | 259.3004 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N.CC(C(O)=O)C1=CC=CC(OC2=CC=CC=C2)=C1
InChI
InChIKey=KWJCCAPFAZGHJF-UHFFFAOYSA-N
InChI=1S/C15H14O3.H3N/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13;/h2-11H,1H3,(H,16,17);1H3
| Molecular Formula | H3N |
| Molecular Weight | 17.0305 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C15H14O3 |
| Molecular Weight | 242.2699 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: http://www.drugbank.ca/drugs/DB00573Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Sources: http://www.drugbank.ca/drugs/DB00573
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Fenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect. Indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00573 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
28.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
105.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Reaction gastrointestinal, Reaction skin... Other AEs: Dyspepsia, Nausea... AEs leading to discontinuation/dose reduction: Reaction gastrointestinal (2%) Other AEs:Reaction skin (1%) Cardiovascular disorder (NOS) (0.5%) Dyspepsia (10%) Sources: Nausea (7.7%) Constipation (7%) Vomiting (2.6%) Abdominal pain (2%) Diarrhea (1.8%) Headache (8.7%) Somnolence (8.5%) Dizziness (6.5%) Tremor (2.2%) Confusion (1.4%) Sweating increased (4.6%) Pruritus (4.2%) Rash (3.7%) Tinnitus (4.5%) Blurred vision (2.2%) Hearing decreased (1.6%) Palpitations (2.5%) Nervousness (5.7%) Asthenia (5.4%) Peripheral edema (5%) Dyspnea (2.8%) Fatigue (1.7%) Upper respiratory infection (1.5%) Nasopharyngitis (1.2%) Gastritis (<1%) Ulcer peptic with perforation (<1%) Ulcer peptic with perforation (<1%) Gastrointestinal hemorrhage (<1%) Anorexia (<1%) Flatulence (<1%) Dry mouth (<1%) Blood in stool (<1%) Alkaline phosphatase increased (<1%) LDH increased (<1%) SGOT increased (<1%) Jaundice (<1%) Cholestatic hepatitis (<1%) Buccal mucosa aphthous ulceration (<1%) Taste metallic (<1%) Pancreatitis (<1%) Atrial fibrillation (<1%) Pulmonary edema (<1%) Electrocardiogram change (<1%) Supraventricular tachycardia (<1%) Renal failure (<1%) Dysuria (<1%) Cystitis (<1%) Hematuria (<1%) Oliguria (<1%) Azotemia (<1%) Anuria (<1%) Nephritis interstitial (<1%) Nephrosis (<1%) Acute papillary necrosis (<1%) Angioedema (<1%) Purpura (<1%) Bruising (<1%) Hemorrhage (<1%) Thrombocytopenia (<1%) Hemolytic anemia (<1%) Aplastic anemia (<1%) Agranulocytosis (<1%) Pancytopenia (<1%) Depression (<1%) Disorientation (<1%) Seizures (<1%) Trigeminal neuralgia (<1%) Burning tongue (<1%) Diplopia (<1%) Optic neuritis (<1%) Exfoliative dermatitis (<1%) Toxic epidermal necrolysis (<1%) Stevens-Johnson syndrome (<1%) Alopecia (<1%) Anaphylaxis (<1%) Urticaria (<1%) Malaise (<1%) Insomnia (<1%) Tachycardia (<1%) Personality change (<1%) Lymphadenopathy (<1%) Mastodynia (<1%) Fever (<1%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cardiovascular disorder (NOS) | 0.5% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Reaction skin | 1% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nasopharyngitis | 1.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Confusion | 1.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Upper respiratory infection | 1.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Hearing decreased | 1.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Fatigue | 1.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Diarrhea | 1.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dyspepsia | 10% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Abdominal pain | 2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Reaction gastrointestinal | 2% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Blurred vision | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Tremor | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Palpitations | 2.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Vomiting | 2.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dyspnea | 2.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Rash | 3.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Pruritus | 4.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Tinnitus | 4.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Sweating increased | 4.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Peripheral edema | 5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Asthenia | 5.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nervousness | 5.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dizziness | 6.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Constipation | 7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nausea | 7.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Somnolence | 8.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Headache | 8.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Acute papillary necrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Agranulocytosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Alkaline phosphatase increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Alopecia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Anaphylaxis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Angioedema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Anorexia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Anuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Aplastic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Atrial fibrillation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Azotemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Blood in stool | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Bruising | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Buccal mucosa aphthous ulceration | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Burning tongue | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Cholestatic hepatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Cystitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Depression | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Diplopia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Disorientation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dry mouth | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Dysuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Electrocardiogram change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Exfoliative dermatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Fever | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Flatulence | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Gastritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Gastrointestinal hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Hematuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Hemolytic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Insomnia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Jaundice | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| LDH increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Lymphadenopathy | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Malaise | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Mastodynia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nephritis interstitial | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Nephrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Oliguria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Optic neuritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Pancreatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Pancytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Personality change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Pulmonary edema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Purpura | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Renal failure | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| SGOT increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Seizures | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Stevens-Johnson syndrome | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Supraventricular tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Taste metallic | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Thrombocytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Toxic epidermal necrolysis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Trigeminal neuralgia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Urticaria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Agranulocytosis associated with fenoprofen. | 1979 Jun 22 |
|
| Cationic vesicles as chiral selector for enantioseparations of nonsteroidal antiinflammatory drugs by micellar electrokinetic chromatography. | 2004 Sep 3 |
|
| Using terahertz pulsed spectroscopy to quantify pharmaceutical polymorphism and crystallinity. | 2005 Apr |
|
| Effects of non-ionic surfactants on isotachophoretic separations of 2-arylpropionic acids. | 2005 Aug 19 |
|
| Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. | 2005 Jan 25 |
|
| Synthesis of fenoprofen and gemfibrozil styrene-maleic acid copolymer conjugates. | 2005 Jun |
|
| Determination of nonsteroidal antiinflammatory drugs in water samples using liquid chromatography coupled with diode-array detector and mass spectrometry. | 2005 Nov |
|
| Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. | 2005 Nov |
|
| Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. | 2005 Nov 29 |
|
| Pharmaceutical liquid crystals: the relevance of partially ordered systems. | 2005 Sep |
|
| Optimization of gas chromatographic method for the enantioseparation of arylpropionic non-steroidal anti-inflammatory drug methyl esters. | 2005 Sep 15 |
|
| The inflammatory process of gout and its treatment. | 2006 |
|
| Antioxidant activity and inhibition of human neutrophil oxidative burst mediated by arylpropionic acid non-steroidal anti-inflammatory drugs. | 2006 Aug |
|
| Vancomycin as chiral selector for enantioselective separation of selected profen nonsteroidal anti-inflammatory drugs in capillary liquid chromatography. | 2006 Aug |
|
| Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8). | 2006 Jun |
|
| Different sample stacking strategies to analyse some nonsteroidal anti-inflammatory drugs by micellar electrokinetic capillary chromatography in mineral waters. | 2006 Jun 9 |
|
| Determination of acidic drugs and caffeine in municipal wastewaters and receiving waters by gas chromatography-ion trap tandem mass spectrometry. | 2006 May 26 |
|
| Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. | 2006 Nov |
|
| Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment. | 2006 Oct |
|
| Prophylaxis of migraine. | 2006 Sep |
|
| Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River. | 2006 Sep |
|
| Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. | 2007 Dec |
|
| Synthesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates. | 2007 Jan |
|
| Enantioseparation by CE with vancomycin as chiral selector: Improving the separation performance by dynamic coating of the capillary with poly(dimethylacrylamide). | 2007 Mar |
|
| Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? | 2007 May |
|
| Rapid online-SPE-MS/MS method for ketoprofen determination in dermal interstitial fluid samples from rats obtained by microdialysis or open-flow microperfusion. | 2007 May 1 |
|
| Stereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumatoid arthritis. | 2007 May 5 |
|
| Removal of selected pharmaceuticals by chlorination, coagulation-sedimentation and powdered activated carbon treatment. | 2008 |
|
| Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. | 2008 |
|
| A combination of statistical and analytical evaluation methods as a new optimization strategy for the quantification of pharmaceutical residues in sewage effluent. | 2008 Apr 21 |
|
| Chiral separation of fluvastatin enantiomers by capillary electrophoresis. | 2008 Aug |
|
| The effect of piroxicam on the formation of postoperative, intraabdominal adhesion in rats. | 2008 Oct |
|
| Evaluation of pharmaceuticals and personal care products as water-soluble molecular markers of sewage. | 2008 Sep 1 |
|
| Using subcritical/supercritical fluid chromatography to separate acidic, basic, and neutral compounds over an ionic liquid-functionalized stationary phase. | 2009 Apr 17 |
|
| Combined use of chiral ionic liquid and CD for MEKC: Part II. Determination of binding constants. | 2009 Aug |
|
| The novel phosphoramidate derivatives of NSAID 3-hydroxypropylamides: synthesis, cytostatic and antiviral activity evaluations. | 2009 Jan |
|
| Synthesis of dehydroabietic acid-modified chitosan and its drug release behavior. | 2009 Jan 5 |
|
| Antioxidant activity of NSAID hydroxamic acids. | 2009 Jun |
|
| Synthesis and biological evaluation of O-methyl and O-ethyl NSAID hydroxamic acids. | 2009 Oct |
|
| Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects. | 2009 Oct |
|
| Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. | 2009 Sep |
|
| The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. | 2010 |
|
| Rapid simultaneous determination of four non-steroidal anti-inflammatory drugs by means of derivative nonlinear variable-angle synchronous fluorescence spectrometry. | 2010 Aug |
|
| Enantiomeric separation of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs by HPLC with hydroxypropyl-beta-cyclodextrin as chiral mobile phase additive. | 2010 Aug |
|
| A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. | 2010 Jul 8 |
|
| Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells. | 2010 Jun |
|
| Use of a robust dehydrogenase from an archael hyperthermophile in asymmetric catalysis-dynamic reductive kinetic resolution entry into (S)-profens. | 2010 May 5 |
|
| Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe2+ chelating activity. | 2010 Sep |
|
| Electrokinetic supercharging focusing in capillary zone electrophoresis of weakly ionizable analytes in environmental and biological samples. | 2010 Sep |
|
| Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping. | 2010 Sep 16 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:10:35 GMT 2025
by
admin
on
Mon Mar 31 21:10:35 GMT 2025
|
| Record UNII |
LR2X880H9H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
66424-48-4
Created by
admin on Mon Mar 31 21:10:35 GMT 2025 , Edited by admin on Mon Mar 31 21:10:35 GMT 2025
|
PRIMARY | |||
|
LR2X880H9H
Created by
admin on Mon Mar 31 21:10:35 GMT 2025 , Edited by admin on Mon Mar 31 21:10:35 GMT 2025
|
PRIMARY | |||
|
126961354
Created by
admin on Mon Mar 31 21:10:35 GMT 2025 , Edited by admin on Mon Mar 31 21:10:35 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
